Acurx Pharmaceuticals, Inc. (ACXP) News
Filter ACXP News Items
ACXP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACXP News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ACXP News From Around the Web
Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 2,463,058 shares of its common stock at a purchase price of $1.015 per share priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered warrants to pur |
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,463,058 shares of its common stock at a purchase price of $1.015 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private pla |
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced that it has received positive regulatory guidance from the EMA during its Scientific Advice Proce |
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year. |
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ... |
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA |
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock NowAcurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ... |
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000A trio of tiny biotech firms have announced plans to invest up to $1 million in Bitcoin. They are not the next MicroStrategy. |
Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin to hold as a treasury reserve asset. |